Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Rectal Neoplasms 8 Colorectal Neoplasms 8 Colonic Neoplasms 4 Stomach Neoplasms 3 Thrombocytopenia 1 Pancreatic Neoplasms 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 Mesothelioma, Malignant 1 Inoperable Esophageal Cancer Stage I-III 1 Hepatecellular Carcinoma 1 Fruquintinib 1 Esophageal Squamous Cell Carcinoma 1 Advanced Metastatic Colorectal Cancer 1 Advanced Gastric Cancer 1 Advanced Colorectal Carcinoma 1 Advanced Colorectal Cancer 1

Interventions

raltitrexed 1 potassium oxonate 1 gimeracil 1 Tegafur 1 S 1 (combination) 1 HMPL-013 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Fruquintinib × raltitrexed × Clear all

NCT06427005 2025-01-22

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

West China Hospital

Phase 2 Recruiting

Fruquintinib

Data powered by HemOnc (CC BY 4.0) Colophon ⚡